Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643707 | 0.83 | CYP3A4 (0.60) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL1116575 | 0.81 | PKM (0.47) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL14838624 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL11548688 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL1948398 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL8348988 | 0.78 | RAPGEF4 (0.52) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL12471164 | 0.78 | KMT2A (0.43) | KMT2AMEN1TDP1LMNAPOLB | |
| SCHEMBL21763819 | 0.78 | PKM (0.44) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL3631632 | 0.78 | KMT2A (0.40) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL30829688 | 0.78 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| EP-1857443-B1 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | ALDH1A1 4660/4885MAPT 4499/4885KMT2A 3584/4885 |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | ALDH1A1 4155/4885MAPT 3390/4885KMT2A 4098/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | ALDH1A1 4155/4885MAPT 3390/4885KMT2A 4098/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | ALDH1A1 707/4885MAPT 1988/4885KMT2A 461/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | ALDH1A1 707/4885MAPT 1988/4885KMT2A 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.